Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy-Reference-Cited by-同舟云学术

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy

Published:2020-09-03 Issue:6 Volume:26 Page:958-965
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Meeks Shannon L.¹^ORCID,Lacroix‐Desmazes Sébastien²^ORCID

Affiliation:

1. Aflac Cancer Center and Blood Disorders Center at Children’s Healthcare of Atlanta Department of Pediatrics Emory University School of Medicine Atlanta GA USA

2. Centre de recherche des Cordeliers, INSERM Sorbonne Université, Université de Paris Paris France

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14123

Reference64 articles.

1. Primary prophylaxis in haemophilia care: Guideline update 2016

2. Guidelines for the management of hemophilia

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries

5. Treatment adherence in hemophilia

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved delivery strategies for biopharmaceuticals;Chinese Chemical Letters;2024-07

2. Chimerism of avian IgY‐scFv and truncated IgG‐Fc: A novel strategy in cross‐species antibody generation and enhancement;Immunology;2024-01-21

3. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. Pathogenesis and treatment of osteoporosis in patients with hemophilia;Archives of Osteoporosis;2023-01-04